Similar articles for PMID: 31064845

Year	Number of Results
1992	1
1995	1
2007	1
2009	1
2011	3
2012	3
2013	2
2014	3
2015	8
2016	10
2017	17
2018	28
2019	21
2020	12
2021	12
2022	10
2023	5
2024	0

1

Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy.

Levi J, Lam T, Goth SR, Yaghoubi S, Bates J, Ren G, Jivan S, Huynh TL, Blecha JE, Khattri R, Schmidt KF, Jennings D, VanBrocklin H. Levi J, et al. Cancer Res. 2019 Jul 1;79(13):3455-3465. doi: 10.1158/0008-5472.CAN-19-0267. Epub 2019 May 7. Cancer Res. 2019. PMID: 31064845 Free PMC article.

2

CD4⁺ and CD8a⁺ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models.

Kristensen LK, Fröhlich C, Christensen C, Melander MC, Poulsen TT, Galler GR, Lantto J, Horak ID, Kragh M, Nielsen CH, Kjaer A. Kristensen LK, et al. Theranostics. 2019 Oct 18;9(26):8221-8238. doi: 10.7150/thno.37513. eCollection 2019. Theranostics. 2019. PMID: 31754392 Free PMC article.

3

¹⁸F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy.

Levi J, Goth S, Huynh L, Lam T, Huynh TL, Schulte B, Packiasamy JA. Levi J, et al. J Nucl Med. 2021 Jun 1;62(6):802-807. doi: 10.2967/jnumed.120.249078. Epub 2020 Nov 6. J Nucl Med. 2021. PMID: 33158906 Free PMC article.

4

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C. Sun R, et al. Lancet Oncol. 2018 Sep;19(9):1180-1191. doi: 10.1016/S1470-2045(18)30413-3. Epub 2018 Aug 14. Lancet Oncol. 2018. PMID: 30120041

5

Intratumoral Tcf1⁺PD-1⁺CD8⁺ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.

Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, Carmona SJ, Scarpellino L, Gfeller D, Pradervand S, Luther SA, Speiser DE, Held W. Siddiqui I, et al. Immunity. 2019 Jan 15;50(1):195-211.e10. doi: 10.1016/j.immuni.2018.12.021. Epub 2019 Jan 8. Immunity. 2019. PMID: 30635237 Free article.

6

Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1^-CD8⁺ Tumor-Infiltrating T Cells.

Kurtulus S, Madi A, Escobar G, Klapholz M, Nyman J, Christian E, Pawlak M, Dionne D, Xia J, Rozenblatt-Rosen O, Kuchroo VK, Regev A, Anderson AC. Kurtulus S, et al. Immunity. 2019 Jan 15;50(1):181-194.e6. doi: 10.1016/j.immuni.2018.11.014. Epub 2019 Jan 8. Immunity. 2019. PMID: 30635236 Free PMC article.

7

Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.

Zhang X, Niedermann G. Zhang X, et al. Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):63-73. doi: 10.1016/j.ijrobp.2018.01.094. Epub 2018 Feb 3. Int J Radiat Oncol Biol Phys. 2018. PMID: 29534901 Free article.

8

Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.

Gray MJ, Gong J, Hatch MM, Nguyen V, Hughes CC, Hutchins JT, Freimark BD. Gray MJ, et al. Breast Cancer Res. 2016 May 11;18(1):50. doi: 10.1186/s13058-016-0708-2. Breast Cancer Res. 2016. PMID: 27169467 Free PMC article.

9

Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.

Weir GM, Hrytsenko O, Quinton T, Berinstein NL, Stanford MM, Mansour M. Weir GM, et al. J Immunother Cancer. 2016 Oct 18;4:68. doi: 10.1186/s40425-016-0169-2. eCollection 2016. J Immunother Cancer. 2016. PMID: 27777777 Free PMC article.

10

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, Liniker E, Kong BY, Cooper AJ, Howle JR, Saw RPM, Jakrot V, Lo S, Thompson JF, Carlino MS, Kefford RF, Long GV, Scolyer RA. Vilain RE, et al. Clin Cancer Res. 2017 Sep 1;23(17):5024-5033. doi: 10.1158/1078-0432.CCR-16-0698. Epub 2017 May 16. Clin Cancer Res. 2017. PMID: 28512174

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

123 results

Results by year